Verve Therapeutics, Inc.

Verve Therapeutics Inc. is a biopharmaceutical company pioneering a new approach to the treatment of cardiovascular diseases. The company focuses on developing gene-editing therapies designed to treat the root causes of these conditions by permanently altering specific genes in the human body. By employing advanced techniques such as base editing, Verve Therapeutics aims to create single-course treatments that offer lifelong benefits, diverging from traditional therapies that typically require ongoing administration. This innovation places Verve Therapeutics at the forefront of the biotech industry, specifically in the gene-editing sector. The company’s work is pivotal in advancing medical research and has the potential to significantly impact healthcare by providing more effective and accessible solutions for cardiovascular patients. Based in the dynamic biotech hub of Cambridge, Massachusetts, Verve Therapeutics collaborates with leading academics and industry experts to continuously push the boundaries of genomic medicine.